BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17470852)

  • 1. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
    Ku GY; Krol G; Ilson DH
    J Clin Oncol; 2007 May; 25(13):e14-6. PubMed ID: 17470852
    [No Abstract]   [Full Text] [Related]  

  • 2. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
    Li J
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab in colorectal cancer.
    Sharieff W
    N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
    J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Utilizing synergism].
    Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
    Aguilera DG; Goldman S; Fangusaro J
    Pediatr Blood Cancer; 2011 Mar; 56(3):491-4. PubMed ID: 21072819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
    Halama N; Herrmann C; Jaeger D; Herrmann T
    Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Boisen MK; Johansen JS; Larsen O; Jensen BV
    Oncology; 2011; 80(1-2):138-9. PubMed ID: 21677460
    [No Abstract]   [Full Text] [Related]  

  • 9. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 10. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Saltz LB
    Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
    Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
    Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
    Venkatramani R; Malogolowkin MH; Mascarenhas L
    Pediatr Blood Cancer; 2014 Apr; 61(4):756-9. PubMed ID: 24115645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
    Zheng H; Chen JZ; Liao WJ; Luo RC
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):689-91. PubMed ID: 16762887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 15. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 16. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of bevacizumab as first-line therapy for colon cancer.
    Marshall J
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.